48 Grafton Street
M13 9XX
+44 (0)161 606 7258
+44 (0)161 606 7348
John Rylands
Epistem is a biotechnology company commercialising adult stem cells in the areas of oncology and gastrointestinal diseases as well as cosmeceutical applications. Epistem develops innovative therapeutics and diagnostic biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.
| Description | Report Date | Published |
|---|---|---|
| Annual Report 2012 | 30-06-2012 | 16-10-2012 |
| Annual Report 2011 | 30-06-2011 | 10-10-2011 |
| Annual Report 2010 | 30-06-2010 | 05-10-2010 |
| Annual Report 2009 | 30-06-2009 | 23-10-2009 |
| Annual Report 2008 | 30-06-2008 | 22-10-2008 |
| Annual Report 2007 | 30-06-2007 | 10-10-2007 |
| Description | Report Date | Published |
|---|---|---|
| Interim Report 2012 | 31-12-2012 | 26-03-2013 |
| Interim Report 2011 | 31-12-2011 | 14-03-2012 |
| Interim Report 2010 | 31-12-2010 | 29-03-2011 |
| Interim Report 2008 | 31-12-2008 | 10-03-2009 |
| Interim Report 2007 | 31-12-2007 | 27-02-2008 |
| Description |
|---|
| Investor Relations |
| Site Map |
| Home |
| Results Index |
| Press Releases |
| Contacts |
| Type | Dividend | Payment Date |
|---|